The Role of Nodes and Nodal Assessment in Diagnosis, Treatment and Prediction in ER+, Node-Positive Breast Cancer.
Charlene Kay, Carlos Martinez-Perez, J Michael Dixon...
https://pubmed.ncbi.nlm.nih.gov/37888087/Actively Recruiting
Led by Natera, Inc. · Updated on 2026-09-23
725
Participants Needed
49
Research Sites
293 weeks
Total Duration
Researchers are evaluating the effectiveness and safety of using circulating tumor DNA ctDNA testing with the Signatera Genome assay to guide the start of CDK46 inhibitor therapy in participants with intermediate-risk, early-stage hormone receptor-positive HR, HER2-negative breast cancer. This approach aims to determine if starting CDK46 inhibitors based on ctDNA results can maintain treatment effectiveness while reducing unnecessary medication use, comparing outcomes to historical data from the NataLEE trial. Participants will undergo ctDNA testing every three months for up to four years. Those testing positive for ctDNA at baseline or during surveillance will start CDK46 inhibitor therapy either ribociclib or abemaciclib combined with hormone therapy for at least two years. Participants who remain ctDNA negative will continue hormone therapy alone with ongoing ctDNA monitoring. Treatment choices follow standard care guidelines and continue until disease progression, unacceptable side effects, or study end. During the study, participants will have regular blood draws for ctDNA testing, hormone therapy, and imaging as needed. Researchers will monitor invasive disease-free survival for up to nine years after surgery. Quality of life assessments and ongoing safety monitoring are part of the follow-up, which will last up to nine years to fully assess cancer outcomes and compare with historical controls.
CONDITIONS
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
C
Chelsea Nihill, MS
J
Jessica Reyes, BS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Natera, Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | ctDNA-guided therapy + CDK4/6 inhibitor plus endocrine therapy (investigational) | Endocrine therapy alone (current standard practice) |
|---|---|---|
| What it is | A treatment approach where Signatera ctDNA testing is used regularly after surgery to monitor for microscopic cancer recurrence, and CDK4/6 inhibitor therapy (ribociclib or abemaciclib) is started only if ctDNA becomes positive. All patients continue standard adjuvant endocrine therapy. | The established adjuvant treatment for ER-positive, HER2-negative stage II breast cancer is endocrine therapy alone, with CDK4/6 inhibitors generally reserved for those with higher-risk features according to guidelines. |
| Role in trial | Investigational approach; all participants receive ctDNA monitoring, and CDK4/6 inhibitor therapy is personalized based on ctDNA findings. Endocrine therapy is continued for all. | Current-care comparator (external context, not part of the trial). |
| Primary use or purpose | To detect molecular signs of cancer recurrence with ctDNA and start targeted CDK4/6 inhibitor therapy, aiming to delay or prevent invasive disease recurrence. | To reduce the risk of breast cancer recurrence and death by using hormone-blocking therapy after surgery in ER+ HER2- stage II breast cancer. |
| How it is given or performed | Blood samples are drawn every 3 months for up to 4 years for Signatera ctDNA testing. If ctDNA is positive, CDK4/6 inhibitor (ribociclib or abemaciclib) is started in addition to ongoing endocrine therapy; minimum CDK4/6 inhibitor duration is 2 years. | Endocrine therapy (such as aromatase inhibitor or tamoxifen) is given by mouth for at least 5 years; blood draws and imaging follow standard surveillance schedules. CDK4/6 inhibitors are used only if high-risk features are present. |
| Clinical evidence status | No randomized trial outcomes yet available for Signatera ctDNA-guided CDK4/6 inhibitor therapy in this population. Ongoing prospective studies suggest ctDNA-positive status is associated with high recurrence risk. | Adjuvant endocrine therapy reduces recurrence and mortality in ER+ HER2- stage II breast cancer; real-world and guideline evidence support established benefit. CDK4/6 inhibitor benefit as add-on therapy is established only for high-risk subgroups. |
| Important limitations | Effectiveness and safety of ctDNA-guided CDK4/6 inhibitor initiation remain unproven; protocol requires several years of follow-up. False negative and false positive ctDNA test results are possible. Real-world application will depend on definitive trial results. | Endocrine therapy alone does not address all recurrence risk. Some patients with high-risk features may benefit from additional CDK4/6 inhibitor therapy. Ongoing research into better recurrence risk stratification. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 4 years
Participants undergo ctDNA testing every 3 months. Those with positive ctDNA will start CDK4/6 inhibitor therapy plus hormone therapy. Participants who remain ctDNA negative continue hormone therapy alone with ongoing monitoring. Treatment continues until disease progression, unacceptable side effects, or study completion.
Quarterly visits for ctDNA testing and assessments
Duration - Up to 9 years
Participants are followed for up to 9 years after surgery with regular blood tests, imaging as needed, and quality-of-life assessments to monitor cancer outcomes and overall health.
Regular follow-up visits as scheduled
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Charlene Kay, Carlos Martinez-Perez, J Michael Dixon...
https://pubmed.ncbi.nlm.nih.gov/37888087/R Cutts, L Ulrich, M Beaney...
https://pubmed.ncbi.nlm.nih.gov/39216186/Yada Kanjanapan, Wayne Anderson, Mirka Smith...
https://pubmed.ncbi.nlm.nih.gov/39294027/Stephen R D Johnston, Nadia Harbeck, Masakazu Toi...
https://pubmed.ncbi.nlm.nih.gov/33630658/David R Nelson, Jacqueline Brown, Aki Morikawa...
https://pubmed.ncbi.nlm.nih.gov/35213669/Beata Smolarz, Anna Zadrożna Nowak, Hanna Romanowicz
https://pubmed.ncbi.nlm.nih.gov/35626173/Rebecca L Siegel, Tyler B Kratzer, Angela N Giaquinto...
https://pubmed.ncbi.nlm.nih.gov/39817679/Mark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed...
https://pubmed.ncbi.nlm.nih.gov/37146605/A Natarajan, S M Tolaney
https://pubmed.ncbi.nlm.nih.gov/39241962/Stacey A Cohen, Minetta C Liu, Alexey Aleshin
https://pubmed.ncbi.nlm.nih.gov/37438589/Natera, Inc.
Lead Sponsor